Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dipraglurant in blepharospasm
NCT05027997Phase 2Completed
- Sponsor
- Addex Therapeutics Ltd
- Start
- Oct 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dipraglurant in benign essential blepharospasm (BEB), sponsored by Addex Therapeutics Ltd. Started Oct 2021; status: completed.
02
Drugs
dipraglurant
03
Conditions
benign essential blepharospasm (BEB)
Beyond the preview
Go deeper on NCT05027997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05027997.